drugset / Trial / NCT05649748
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Timeline
- Start
- 2023-03-07
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Treprostinil Palmitil | Small molecule | 80 ug | Inhaled |
| Subject | Treprostinil Palmitil | Small molecule | 640 ug | Inhaled |
| Subject | Treprostinil Palmitil | Small molecule | 1280 ug | Inhaled |